Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.
Royal Philips recently announced that its e-Alert was awarded “Most Innovative IoT Solution” at the World Communication Awards, Dec. 19 in London. The World Communication Awards are recognized as the most prestigious awards in the global telecom industry, highlighting innovation and outstanding industry performance.
Simon Fraser University researchers have found that high-resolution brain scans, coupled with computational analysis, could play a critical role in helping to detect concussions that conventional scans might miss.
Radiology departments have many different needs and face a wide variety of challenges that can impact their departments ...
The capsule endoscopy systems offer a hands-free and highly accurate imaging modality for healthcare practitioners. A ...
January 2, 2017 — Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed ...
January 2, 2017 — Radiologists may be uniquely positioned to identify elder abuse, but they do not have training or ...
Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...
December 29, 2016 — Significant differences exist in breast cancer screening rates for racial groups in the United ...
December 28, 2016 – A new Harvey L. Neiman Health Policy Institute series of reports explores the impact of the Medicare ...
December 29, 2016 — The Department of Health and Human Services (HHS) finalized new Medicare alternative payment models ...
Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...
December 28, 2016 — Pregnancy involves radical hormone surges and biological adaptations, but the effects on the brain ...
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States ...
A discussion with Andy Colbert, managing director and founding member of Ziegler’s Healthcare Investment Banking ...
eHealth Saskatchewan plays a vital role in providing IT services to patients, health care providers, and partners such ...
Kim Garriott, principal consultant for Logicalis Healthcare Solutions, explains the concept of value-based imaging and ...
December 23, 2016 — According to new research from the Harvey L. Neiman Health Policy Institute, state tort reform has ...
A University of Rochester Medical Center study shows that when tumors are treated with radiotherapy, the benefits can be hijacked by the treatment's counteraction to trigger inflammation and dampen the body's immune response.
Insightec Ltd. announced that the Exablate Prostate system received CE Mark for treating locally-confined prostate cancer with MR-guided Focused Ultrasound (MRgFUS).
If you're thinking about taking up running as your New Year's resolution and still need some convincing, consider this: MRI scans reveal that endurance runners' brains have greater functional connectivity than the brains of more sedentary individuals.
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA).
The Imaging Technology News (ITN) website had a record year with more than 1.04 million page views in 2016. Here are the ...
January 03, 2017 